Clinical Trial Design of AT-02 Phase 2 Open Label Extension Study in Systemic Amyloidosis PC143 (#519)
Spencer Guthrie(Heidelberg University), Matthew Meldorf, Olga Motorna(The University of Melbourne), Claire D. Sherman(Naples Anesthesia & Physician Associates), Joseph B. Selvanayagam(Flinders Medical Centre), James Hare(The Alfred Hospital), W. Brett, Dariusz Korczyk, Joban Vaishnav(Johns Hopkins University), Ahmad Masri(Oregon Health & Science University), Brian Drachman(Penn Presbyterian Medical Center), Graham S. Hillis(The University of Western Australia), Vasvi Singh(HCA Midwest Division), Marianna Fontana(Amyloidosis Foundation), Gregory Bell(Naples Anesthesia & Physician Associates), Desmond Julian
Cited by 0
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
|The Lancet|2015|984
Myocardial Injury after Noncardiac Surgery
|Anesthesiology|2014|979